Moving towards personalized treatments of immune-related adverse events

B cells are associated with survival and immunotherapy response in sarcoma

(2020) Florent Petitprez et al.   NATURE

Tertiary lymphoid structures improve immunotherapy and survival in melanoma

(2020) Rita Cabrita et al.   NATURE

B cells and tertiary lymphoid structures promote immunotherapy response

(2020) Beth A. Helmink et al.   NATURE

Resolution of Pembrolizumab‐Associated Steroid‐Refractory Lichenoid Dermatitis with Cyclosporine

(2019) Emma Fixsen et al.   ONCOLOGIST

Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience

(2019) Omar Mamlouk et al.   Journal for ImmunoTherapy of Cancer

Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab

(2019) Hao Chi Zhang et al.   Journal for ImmunoTherapy of Cancer

Cold agglutinin disease as a new immune-related adverse event associated with anti-PD-L1s and its treatment with rituximab

(2019) Martin Dutertre et al.   EUROPEAN JOURNAL OF CANCER

Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors

(2019) Moshe C. Ornstein et al.   Clinical Genitourinary Cancer

Incidence and clinical pattern of immune related adverse effects (irAE) due to immune checkpoint inhibitors (ICI).

(2019) Bicky Thapa et al.   JOURNAL OF CLINICAL ONCOLOGY

Correlation of immune-related adverse events with peripheral baseline immune markers and overall survival in patients with metastatic melanoma on ipilimumab and chemotherapy.

(2019) Khashayar Esfahani et al.   JOURNAL OF CLINICAL ONCOLOGY

Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) to predict succeeding onset of immune-related adverse events (irAEs).

(2019) Rika Kizawa et al.   JOURNAL OF CLINICAL ONCOLOGY

Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition.

(2019) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

(2019) Elisabeth Perez-Ruiz et al.   NATURE

Correction to: The pathogenicity of Th17 cells in autoimmune diseases

(2019) Keiko Yasuda et al.   Seminars in Immunopathology

IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy

(2019) Daniel Johnson et al.   Cancer Immunology Research

Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer

(2019) Fiamma Berner et al.   JAMA Oncology

Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature

(2019) Noha Abdel-Wahab et al.   Journal for ImmunoTherapy of Cancer

The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?

(2019) A Elkrief et al.   ANNALS OF ONCOLOGY

Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab

(2019) S. D. Saibil et al.   Current Oncology

Treatment Outcomes of Immune-Related Cutaneous Adverse Events

(2019) Gregory S. Phillips et al.   JOURNAL OF CLINICAL ONCOLOGY

A Multidisciplinary Toxicity Team for Cancer Immunotherapy–Related Adverse Events

(2019) Jarushka Naidoo et al.   Journal of the National Comprehensive Cancer Network

Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy

(2019) Khashayar Esfahani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis

(2019) Joe-Elie Salem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase 3, Double‐Blind, Randomized Controlled Trial

(2019) Roy Fleischmann et al.   Arthritis & Rheumatology

Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions

(2019) Francesca Romana Mariotti et al.   Frontiers in Immunology

Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation

(2019) Tawnie J Braaten et al.   ANNALS OF THE RHEUMATIC DISEASES

Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade

(2019) Nicolas Jacquelot et al.   CELL RESEARCH

The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis

(2019) Karthik Suresh et al.   JOURNAL OF CLINICAL INVESTIGATION

Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events

(2019) Yousef R. Badran et al.   Journal for ImmunoTherapy of Cancer

Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis

(2019) Hamzah Abu-Sbeih et al.   Journal for ImmunoTherapy of Cancer

1756PDThe ImmunoTOX multidisciplinary board: A descriptive study of collaborative management of immune-related adverse events

(2019) J-M Michot et al.   ANNALS OF ONCOLOGY

Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports

(2019) Koji Yoshino et al.   BMC CANCER

Oncolysis without viruses — inducing systemic anticancer immune responses with local therapies

(2019) Oliver Kepp et al.   Nature Reviews Clinical Oncology

B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma

(2019) Johannes Griss et al.   Nature Communications

Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation

(2019) Khashayar Esfahani et al.   Nature Communications

Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease

(2018) Noha Abdel-Wahab et al.   ANNALS OF INTERNAL MEDICINE

High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma

(2018) Alexander T. Faje et al.   CANCER

Combined blockade of IL-6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment

(2018) Hirotake Tsukamoto et al.   CANCER RESEARCH

When worlds collide: Th17 and Treg cells in cancer and autoimmunity

(2018) Hannah M. Knochelmann et al.   Cellular & Molecular Immunology

The interaction between environmental triggers and epigenetics in autoimmunity

(2018) Bruce Richardson   CLINICAL IMMUNOLOGY

Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects

(2018) Charlotte Schwab et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Early B cell changes predict autoimmunity following combination immune checkpoint blockade

(2018) Rituparna Das et al.   JOURNAL OF CLINICAL INVESTIGATION

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Brief report: Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab

(2018) Susan Combs Scott et al.   Journal of Thoracic Oncology

Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors

(2018) Michael F. Gowen et al.   Journal of Translational Medicine

JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non–small Cell Lung Cancers

(2018) Sean P. Pitroda et al.   MOLECULAR CANCER THERAPEUTICS

Immune Checkpoint Inhibitor‐Associated Myocarditis

(2018) Sarju Ganatra et al.   ONCOLOGIST

Rheumatologic symptoms in oncologic patients on PD-1 inhibitors

(2018) Wilson F. Kuswanto et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Safety of Tocilizumab in Rheumatoid Arthritis Patients with Resolved Hepatitis B Virus Infection: Data from Real-World Experience

(2018) Sung Soo Ahn et al.   YONSEI MEDICAL JOURNAL

mTOR complexes differentially orchestrates eosinophil development in allergy

(2018) Chen Zhu et al.   Scientific Reports

Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma

(2018) Alexander N. Shoushtari et al.   JAMA Oncology

Programmed Cell Death Ligand 1–Induced Coma From Diffuse Cerebritis

(2018) Ploa Desforges et al.   Journal of Oncology Practice

Refractory Neutropenia Secondary to Dual Immune Checkpoint Inhibitors That Required Second-Line Immunosuppression

(2018) Nicholas Meti et al.   Journal of Oncology Practice

Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1

(2018) Andrew L Mammen et al.   ANNALS OF THE RHEUMATIC DISEASES

Enterocolitis due to immune checkpoint inhibitors: a systematic review

(2018) Emilie Soularue et al.   GUT

Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade

(2018) Joy Hsu et al.   JOURNAL OF CLINICAL INVESTIGATION

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer

(2018) Kathryn C. Arbour et al.   JOURNAL OF CLINICAL ONCOLOGY

Rheumatic immune-related adverse events from cancer immunotherapy

(2018) Leonard H. Calabrese et al.   Nature Reviews Rheumatology

Advanced model systems and tools for basic and translational human immunology

(2018) Lisa E. Wagar et al.   Genome Medicine

The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond

(2018) Nicolo Costantino Brembilla et al.   Frontiers in Immunology

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

(2018) Daniel Y. Wang et al.   JAMA Oncology

Inflammatory Arthritis Induced by Pembrolizumab in a Patient With Head and Neck Squamous Cell Carcinoma

(2018) Nikolaos Spathas et al.   Frontiers in Oncology

Immune dysregulation in cancer patients developing immune-related adverse events

(2018) Shaheen Khan et al.   BRITISH JOURNAL OF CANCER

Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy

(2018) Su Y. Lim et al.   CLINICAL CANCER RESEARCH

Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors

(2018) Alvaro Moreira et al.   EUROPEAN JOURNAL OF CANCER

Molecular mimicry and autoimmunity

(2018) Manuel Rojas et al.   JOURNAL OF AUTOIMMUNITY

Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis

(2018) Yinghong Wang et al.   NATURE MEDICINE

Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors

(2018) Emma C. de Moel et al.   Cancer Immunology Research

Anakinra Therapy for Non-cancer Inflammatory Diseases

(2018) Giulio Cavalli et al.   Frontiers in Pharmacology

Gut microbiome structure and metabolic activity in inflammatory bowel disease

(2018) Eric A. Franzosa et al.   Nature Microbiology

A severe case of neuro-Sjögren’s syndrome induced by pembrolizumab

(2018) Jaqueline Ghosn et al.   Journal for ImmunoTherapy of Cancer

Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study

(2018) Hamzah Abu-Sbeih et al.   Journal for ImmunoTherapy of Cancer

Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis

(2018) Daniel H Johnson et al.   Journal for ImmunoTherapy of Cancer

IL-1 and IL-1 regulatory pathways in cancer progression and therapy

(2017) Alberto Mantovani et al.   IMMUNOLOGICAL REVIEWS

Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

(2017) Jarushka Naidoo et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

(2017) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

The Role of IL-17 and Related Cytokines in Inflammatory Autoimmune Diseases

(2017) Taku Kuwabara et al.   MEDIATORS OF INFLAMMATION

Is autoimmunity the Achilles' heel of cancer immunotherapy?

(2017) Carl H June et al.   NATURE MEDICINE

The role of IL-6 in host defence against infections: immunobiology and clinical implications

(2017) Stefan Rose-John et al.   Nature Reviews Rheumatology

Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade

(2017) Khashayar Esfahani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

(2017) Kim A. Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

(2017) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

(2017) V. Gopalakrishnan et al.   SCIENCE

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

(2017) Bertrand Routy et al.   SCIENCE

Corticosteroids and infliximab impair the performance of interferon-γ release assays used for diagnosis of latent tuberculosis

(2017) Alexander Edwards et al.   THORAX

Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature

(2017) Laura C. Cappelli et al.   ARTHRITIS CARE & RESEARCH

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma

(2017) Florie Bertrand et al.   Nature Communications

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2017) Angel Garcia-Diaz et al.   Cell Reports

JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer

(2017) Chunwan Lu et al.   OncoImmunology

Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade

(2017) Chipman RG Stroud et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy

(2017) Eileen Shiuan et al.   Journal for ImmunoTherapy of Cancer

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

(2017) I. Puzanov et al.   Journal for ImmunoTherapy of Cancer

Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer

(2017) James Luke Godwin et al.   Journal for ImmunoTherapy of Cancer

Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis.

(2017) M. K. Callahan et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire

(2016) David Y. Oh et al.   CANCER RESEARCH

IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer

(2016) Thomas A Mace et al.   GUT

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

(2016) Douglas B. Johnson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities

(2016) Sumit K. Subudhi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Re-examining the Nature and Function of Self-Reactive T cells

(2016) David M. Richards et al.   TRENDS IN IMMUNOLOGY

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

(2016) Krista Dubin et al.   Nature Communications

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

(2016) Daniel Sanghoon Shin et al.   Cancer Discovery

Ipilimumab-associated Hepatitis

(2015) Melanie Johncilla et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging

(2015) Andras Perl   Annals of the New York Academy of Sciences

Intravenous immunoglobulin as clinical immune-modulating therapy

(2015) Laurent Gilardin et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Interleukin-6 as a Therapeutic Target

(2015) J.-F. Rossi et al.   CLINICAL CANCER RESEARCH

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

(2015) Troy Z. Horvat et al.   JOURNAL OF CLINICAL ONCOLOGY

IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases

(2015) Michele W L Teng et al.   NATURE MEDICINE

Rapamycin inhibition of eosinophil differentiation attenuates allergic airway inflammation in mice

(2015) Wen Hua et al.   RESPIROLOGY

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

(2015) M. Vetizou et al.   SCIENCE

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

(2015) Ahmad A. Tarhini et al.   Journal for ImmunoTherapy of Cancer

Systemic use of tumor necrosis factor alpha as an anticancer agent

(2015) Nicholas J. Roberts et al.   Oncotarget

Role of the Microbiota in Immunity and Inflammation

(2014) Yasmine Belkaid et al.   CELL

The Coinhibitory Receptor CTLA-4 Controls B Cell Responses by Modulating T Follicular Helper, T Follicular Regulatory, and T Regulatory Cells

(2014) Peter T. Sage et al.   IMMUNITY

Transcriptional Complex Formation of c-Fos, STAT3, and Hepatocyte NF-1  Is Essential for Cytokine-Driven C-Reactive Protein Gene Expression

(2014) T. Nishikawa et al.   JOURNAL OF IMMUNOLOGY

Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions

(2014) Norihiro Nishimoto et al.   Modern Rheumatology

IL-6 biology: implications for clinical targeting in rheumatic disease

(2014) Leonard H. Calabrese et al.   Nature Reviews Rheumatology

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

(2014) Eun Bong Lee et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody

(2014) S. Iwama et al.   Science Translational Medicine

How Steroids Steer T Cells

(2014) Claude Libert et al.   Cell Reports

A balance of interleukin-12 and -23 in cancer

(2013) Shin Foong Ngiow et al.   TRENDS IN IMMUNOLOGY

Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma

(2012) L. Albiges et al.   ANNALS OF ONCOLOGY

Regulation of Immune Responses by mTOR

(2012) Jonathan D. Powell et al.   Annual Review of Immunology

PD-1 is a novel regulator of human B-cell activation

(2012) Marie-Laure Thibult et al.   INTERNATIONAL IMMUNOLOGY

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

(2012) Charles A. Dinarello et al.   NATURE REVIEWS DRUG DISCOVERY

Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer

(2011) Marina Lesina et al.   CANCER CELL

Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy

(2011) Katarzyna D. Chmiel et al.   JOURNAL OF CLINICAL ONCOLOGY

Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)

(2011) Kamran Ghoreschi et al.   JOURNAL OF IMMUNOLOGY

NOD2, an intracellular innate immune sensor involved in host defense and Crohn's disease

(2011) W Strober et al.   Mucosal Immunology

Interleukin-17 Contributes to the Pathogenesis of Autoimmune Hepatitis through Inducing Hepatic Interleukin-6 Expression

(2011) Li Zhao et al.   PLoS One

Autoinflammatory Disease Reloaded: A Clinical Perspective

(2010) Daniel L. Kastner et al.   CELL

Myocarditis associated with infliximab

(2010) Eoin Slattery et al.   INFLAMMATORY BOWEL DISEASES

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials

(2010) L. Campbell et al.   RHEUMATOLOGY

IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated Cancer

(2009) Sergei Grivennikov et al.   CANCER CELL

Interleukin-1 and IL-23 Induce Innate IL-17 Production from γδ T Cells, Amplifying Th17 Responses and Autoimmunity

(2009) Caroline E. Sutton et al.   IMMUNITY

Tumor Necrosis Factor and the consequences of its ablation in vivo

(2009) G.A. Efimov et al.   MOLECULAR IMMUNOLOGY

An Autoinflammatory Disease Due to Homozygous Deletion of theIL1RNLocus

(2009) Sreelatha Reddy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Circulating CD21low B cells in common variable immunodeficiency resemble tissue homing, innate-like B cells

(2009) M. Rakhmanov et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases

(2008) Justin M. Ko et al.   JOURNAL OF DERMATOLOGICAL TREATMENT